Evidence map›Paper›PMID 40665262›Full record

ArticleBiomedical engineering online2025

In vitro study on the osteoimmunological potential of magnesium implants (WE43MEO).

Sabrin Aydin, Ana Prates Soares, Heilwig Fischer, Raphael Silvan Knecht, Alexander Kopp, Katharina Schmidt-Bleek, Max Heiland, Carsten Rendenbach

Abstract read
In one paragraph

Article in Biomedical engineering online, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Osteogenesis-synchronized degradation of MgBiomedical engineering online · 2026
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sabrin AydinDepartment of Oral and Maxillofacial Surgery, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, and Humboldt-Universität Zu Berlin, and Berlin Institute of Health, Berlin, Germany. sabrin.aydin@charite.de.
Ana Prates SoaresDepartment of Oral and Maxillofacial Surgery, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, and Humboldt-Universität Zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Heilwig FischerDepartment of Oral and Maxillofacial Surgery, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, and Humboldt-Universität Zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Raphael Silvan KnechtJulius Wolff Institute for Biomechanics and Musculoskeletal Regeneration, Berlin Institute of Health at Charité-Universitätsmedizin Berlin, Berlin, Germany.
Alexander KoppMeotec GmbH, Aachen, Germany.
Katharina Schmidt-BleekJulius Wolff Institute for Biomechanics and Musculoskeletal Regeneration, Berlin Institute of Health at Charité-Universitätsmedizin Berlin, Berlin, Germany.
Max HeilandDepartment of Oral and Maxillofacial Surgery, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, and Humboldt-Universität Zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Carsten RendenbachDepartment of Oral and Maxillofacial Surgery, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, and Humboldt-Universität Zu Berlin, and Berlin Institute of Health, Berlin, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionBioresorbable implants significantly advance orthopedics and regenerative medicine, offering advantages over permanent implants for bone regeneration. They eliminate the need for secondary surgery and reduce long-term risks associated with permanent implants. Magnesium-based alloys are particularly promising, as their biocompatibility and mechanical properties are similar to bone. However, the degradation of magnesium is associated with physiological challenges that need to be better understood.

objectiveThe primary focus of this in vitro study was to investigate the osteogenic and immunomodulatory potential of WE43, a promising magnesium alloy tailored for clinical applications, and to test its osteogenic effect when a plasma electrolytic oxidation (PEO) surface modification is added.

resultsThe present data revealed that WE43 implants show excellent biocompatibility and bioactivity, promoting the viability of osteoblasts and enhancing the expression of osteogenic genes, specially Alpl and Tnfrsf11b. PEO surface modification did not further enhance osteogenic differentiation. Notably, WE43 implants elicited a minimal inflammatory response in RAW264.7 murine macrophages, indicating good biocompatibility. Furthermore, supernatant collected from RAW264.7 murine macrophages cultured with WE43 implants stimulated the Alpl expression in MC3T3-E1 murine osteoblasts, demonstrating their potential osteoimmune effect.

conclusionThe present findings highlight the promising potential of WE43 alloy as a biocompatible and osteoinductive biomaterial for bone regeneration applications. Their osteoimmune modulation further demonstrates the advantages of using this alloy system. Specifically, a minimal, well-controlled inflammatory response can promote a faster transition to the bone remodeling phase, leading to quicker and more effective bone regeneration. METHODOLOGY: A comprehensive in vitro investigation was conducted to assess the impact of both WE43 and WE43 PEO on the viability, Alkaline Phosphatase (ALP) expression, osteogenic gene expression (Alpl, Tnfrsf11b, and Bglap), and mineralization of MC3T3-E1 murine osteoblasts. The osteoimmunomodulatory response to WE43 was evaluated using RAW264.7 murine macrophages by assessing their response to direct contact with the alloy.

Indexed as

AlloysMagnesiumProstheses and ImplantsAlkaline PhosphataseAnimalsBiocompatible MaterialsCell DifferentiationCell SurvivalMacrophagesMaterials TestingMiceOsteoblastsOsteogenesisRAW 264.7 CellsAlkaline PhosphataseAlloysBiocompatible MaterialsMagnesium

Identifiers

PMID40665262
PMCPMC12265262

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.